AstraZeneca Stock Leads 3 Cash Flow Bargains Trading Below Fair Value

With inflation paths uneven, bond yields high and energy prices driving market mood, many investors are again looking at cash flow and valuation as their anchor. The Undervalued Stocks Based On Cash Flows screener focuses on companies where SWS DCF analysis suggests the market price sits below estimated fair value. That points you toward businesses where expected cash generation does more of the talking than short term sentiment. In this article you will see three stocks from that screener that currently stand out, along with a clear explanation of why their cash flow profiles and valuations are attracting attention.

AstraZeneca (LSE:AZN)

Overview: AstraZeneca is a global biopharmaceutical company based in Cambridge that discovers, develops, manufactures and sells prescription medicines across cancer, cardiovascular, metabolic, respiratory, immunology, vaccines and rare diseases, with a broad portfolio that includes oncology blockbusters and treatments for chronic conditions.

Operations: AstraZeneca generates about US$61.4b in revenue, almost entirely from pharmaceuticals.

Market Cap: £195.9b

AstraZeneca attracts investor attention because it combines a large oncology and rare disease franchise with high profitability, including net margins at 17% and a current ROE of 20.8%. The stock currently trades below Simply Wall St fair value estimates, while analysts’ targets are positioned meaningfully above the current price, which is unusual for a company of this scale. At the same time, investors may wish to weigh factors such as dependence on a limited number of blockbuster drugs, high R&D expenditure, a sizeable debt load, and recent clinical and regulatory developments that have influenced sentiment. The company’s late-stage pipeline, recent approvals and stated long-term revenue ambitions are key elements for investors to examine when considering the current valuation.

AstraZeneca’s high margins and sizeable oncology exposure are only half the story. See how the current valuation compares to its cash generation in the DCF valuation analysis for AstraZeneca and what that implies for pipeline risk and long term returns.

Foresight Group Holdings (LSE:FSG)

Overview: Foresight Group Holdings is a London based asset manager that runs infrastructure, private equity, venture capital and listed funds, with a focus on renewable energy, social and digital infrastructure, and providing capital to smaller businesses across the UK, Europe and Australia.

Operations: Foresight Group Holdings generates about £114.8m in revenue from Real Assets and £50.1m from Private Equity, with most revenue coming from the United Kingdom and Australia.

Market Cap: £513m

Foresight Group Holdings may appeal to investors seeking exposure to long term themes such as energy transition and infrastructure through a specialist manager. Revenue and earnings have recently grown, net margins sit around 27.7% and the P/E is below both peer and industry averages. Some investors may view this as indicating that the stock does not fully reflect its assets under management ambitions or ongoing share buybacks. At the same time, the business leans on performance fees, external borrowing and concentrated exposure to UK and European policy for renewables, so earnings can be sensitive if fundraising or regulation disappoints. The fuller story lies in how its fundraising pace, product mix shift and capital returns influence cash flows and valuation over time.

Foresight Group Holdings sits at an interesting intersection, where growing revenue, firm margins and a below peer P/E could be masking a more complex story. Get the full picture in the analysis report for Foresight Group Holdings

Diaceutics (AIM:DXRX)

Overview: Diaceutics is a Belfast based diagnostics commercialization company that helps pharma and biotech firms get the right tests used for the right patients. It uses its DXRX platform and data analytics to connect laboratories, doctors and drug makers in precision medicine.

Operations: Diaceutics generates about £38.4m in revenue from Medical Labs & Research, with around £35.8m coming from North America and smaller contributions from the UK, Europe, and Asia and Rest of World.

Market Cap: £121.5m

Diaceutics stands out because it operates at the intersection of diagnostics and precision medicine. Its DXRX platform turns detailed lab and physician data into better targeting for high value therapies. The company has only recently moved into profit. Analysts currently project earnings growth and see the stock trading below their fair value estimates, which suggests the market may not be fully reflecting that earnings profile. At the same time, return on equity is currently very low at 0.2% and the balance sheet leans heavily on higher risk external funding, so execution and funding costs are important considerations. For investors willing to accept those trade offs, Diaceutics offers a mix of a data focused model, improving profitability and a discounted valuation within the screener’s cash flow lens.

Diaceutics looks like an earnings story that the market has not fully joined yet, with its DXRX platform and recent move into profit only part of the picture. See how the analyst forecasts for Diaceutics fits with its low ROE and funding risks before the next chapter becomes clearer.

The three stocks in this article are just a starting point, as the full Undervalued Stocks Based On Cash Flows screener has surfaced 40 more companies with cash flow stories that sit within the broader Undervalued Stocks Based On Cash Flows screener. Use Simply Wall St to identify and analyze the specific catalysts and narratives that matter to you so you can focus on the highest conviction ideas from that list.

Take Control of Your Investment Journey

If AstraZeneca or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

Some of the most interesting stories begin to move quietly, then pick up breakout momentum before most investors even notice. Consider these fresh ideas while it matters and aim to get in early.

• Spot resilient opportunities that can keep moving when others stall by reviewing a curated set of 8 resilient stocks with low risk scores that put balance sheet strength and stability up front.
• Target income ideas with yield potential by scanning a hand picked lineup of 5 dividend fortresses that focus on consistency, coverage and staying power.
• Follow structural demand in critical materials by checking a focused basket of 8 top copper producer stocks that are tied to long term electrification and infrastructure themes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com